Financial Data and Key Metrics Changes - The net loss attributable to common stockholders for Q4 2025 was $36.9 million, representing an 11% year-over-year improvement, while the full year net loss was $116.7 million, reflecting a 24% improvement [22] - Non-GAAP adjusted net loss for Q4 2025 was $17.5 million, a 9% improvement year-over-year, and for the full year, it was $54.1 million, showing a 49% improvement [22] - Total consolidated revenues for Q4 2025 were $29.5 million, a 7% year-over-year increase, while full year revenues were $130.4 million, essentially flat compared to the previous year [23] Business Line Data and Key Metrics Changes - Hospitality segment revenues declined by 23% in Q4 2025 on a pro forma basis, primarily due to lower performance at the Tin Building [24] - Entertainment segment revenues increased by 68% year-over-year in Q4 2025, driven by the internalization of Enchant operations in Las Vegas [28] - Landlord segment rental revenue increased by 14% year-over-year in Q4 2025, mainly from private events rental revenue [30] Market Data and Key Metrics Changes - The Seaport neighborhood was approximately 90% leased or programmed as of December 31, 2025, leaving roughly 47,000 sq ft of vacancy [16] - The company has leased or programmed more than 220,000 sq ft since becoming a standalone public company, which is expected to result in additional stabilized EBITDA of over $30 million [16] Company Strategy and Development Direction - The company aims to position itself as a scalable, real estate-centric hospitality and entertainment company, focusing on improving operations and expanding offerings [3] - The sale of 250 Water Street is expected to generate net proceeds of approximately $75 million, eliminating $7 million of annual cash burn related to interest expense [5][6] - The company plans to expand the Pier 17 event space from 17,500 sq ft to over 40,000 sq ft, targeting premium corporate and social events [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress and the potential for long-term financial stability, particularly with the new Balloon Museum and other attractions [9][40] - The company anticipates continued margin improvement in 2026 across its operations, particularly in Las Vegas, as it applies learnings from previous experiences [18] Other Important Information - The company has received board approval for a $150 million shelf registration statement and a $50 million stock repurchase program, providing flexibility for future capital allocation [18] - Capital expenditures in Q4 2025 totaled $2.8 million, with full year expenditures at $30.8 million, primarily related to various development projects [38] Q&A Session Summary Question: How much of the $163 million cash is committed to current projects? - The company expects to spend around $70 million-$90 million to stabilize current projects, having spent about $30 million in 2025 [43] Question: What are the criteria for the buyback program? - The buyback program will be executed opportunistically, with no specific parameters or timing publicly disclosed [62][63] Question: How does the Balloon Museum complement the Meow Wolf experience? - Both attractions are seen as complementary, providing a full day of activities for visitors and enhancing the overall appeal of the Seaport [67][68] Question: What is the status of the apartment building at 85 South Street? - The building is nearly fully leased and cash flowing, with significant interest in the marketing process for potential monetization [70] Question: How does the company view the Las Vegas properties compared to New York? - The Las Vegas ballpark is considered a valuable asset, with opportunities for improved profitability through better cost controls and creative ticketing strategies [74]

Financial Data and Key Metrics Changes - In Q4, net sales reached $124.4 million, representing a 4.1% year-over-year growth, marking the highest quarter of net sales in the company's history [8][18] - For the full year, net sales totaled $437.5 million, up 3.6% year-over-year [8][18] - Adjusted EBITDA for Q4 was $4.2 million, or a 3.3% margin, while full year adjusted EBITDA was $12 million, or a 2.7% margin [10][22] - Gross margin for Q4 was 55.9%, with a full year gross margin of 57.5%, reflecting a decline due to rising metal prices [9][19] Business Line Data and Key Metrics Changes - Fine jewelry bookings grew 34% year-over-year in Q4, reaching 23% of total bookings mix for the quarter and 17% for the full year [11][12] - The fine jewelry segment is projected to become a $100 million annual business, significantly increasing from its nascent stage five years ago [6][12] - Engagement rings saw approximately 1% year-over-year growth in bookings during the second half of the year, while wedding and anniversary bands delivered double-digit growth [13] Market Data and Key Metrics Changes - The company experienced strong demand for fine jewelry, with almost half of new customers discovering the brand through this segment in Q4 [11] - The overall market environment is characterized by historically high metal costs, with gold prices up approximately 67% year-over-year and platinum up 144% [20][21] Company Strategy and Development Direction - The company aims to build itself into the most loved and trusted jewelry brand, focusing on expanding beyond its core bridal business into fine jewelry [5][6] - The strategy includes enhancing customer experiences through innovative retail formats and personalized shopping experiences [7][15] - The company plans to continue its asset-light business model, leveraging technology and processes for long-term profitable growth [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the challenging cost environment, emphasizing the agility of their business model and pricing strategies [10][21] - For 2026, the company expects net sales to grow in the mid-single-digit percentage range, with continued headwinds in gross margin due to high metal prices [27][28] - Management highlighted the importance of fine jewelry as a growth driver and the ongoing diversification from bridal heritage [40] Other Important Information - The company ended Q4 with approximately $79.1 million in cash and no debt on the balance sheet [26] - A mission report was released, marking two decades of impact and outlining progress toward sustainability and inclusion initiatives [16][17] Q&A Session Summary Question: Expectations for AOV growth and hedging strategies - Management noted that AOV was slightly down in Q4, but ASPs were up across the assortment, driven by strong performance in fine jewelry [34][36] Question: Key bookings growth drivers for 2026 - Management highlighted fine jewelry and showroom strategy as key growth drivers, with continued brand awareness and customer discovery through fine jewelry [39][40] Question: Gross margin outlook for 2026 - Management expects gross margin to be in the mid-50s% range for the year, with potential for mitigation of headwinds through pricing and operational actions [42][43] Question: Operating expense leverage opportunities - Management emphasized disciplined management of operating expenses while driving marketing efficiencies to offset metal pricing impacts [49][50] Question: Potential for negative EBITDA in Q2 or Q3 - Management confirmed that most profitability is expected in Q4, with the potential for challenges in earlier quarters due to fixed operating costs [51][52]

Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $27.4 million or $0.27 per share, compared to a net loss of $23.2 million or $0.33 per share in Q4 2024, indicating an increase in losses year-over-year [31][32] - R&D expenses in Q4 2025 were $18.4 million, down from $19.8 million in the same period of 2024, primarily due to the completion of the Phase 2b trial [30] - G&A expenses increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, driven by one-time charges related to executive transition and increased professional fees [31] Business Line Data and Key Metrics Changes - The company is focused on advancing pemvidutide for liver diseases, particularly MASH, with promising results from Phase 2 trials showing early MASH resolution and anti-fibrotic activity [9][16] - The Phase 2 AUD trial completed enrollment ahead of schedule, with top-line data expected in Q3 2026 [14][23] - The Phase 2 trial assessing pemvidutide in ALD is expected to complete enrollment in 2026 [14] Market Data and Key Metrics Changes - Market research indicated significant unmet needs among MASH patients, particularly for those who have discontinued semaglutide due to tolerability issues [25][26] - Physicians expressed a high unmet need for therapies that preserve lean muscle mass in MASH patients, highlighting the potential competitive advantage of pemvidutide [25][26] Company Strategy and Development Direction - The company aims to strengthen its foundation for the advancement of pemvidutide and has enhanced its leadership team with expertise in liver disease and late-stage clinical development [11] - A $75 million capital raise was completed to support the planned initiation of the Phase 3 trial for pemvidutide [12] - The company is preparing for a pivotal Phase 3 trial with a focus on MASH, aligning with FDA guidance on trial design and endpoints [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pemvidutide to address significant unmet needs in liver diseases, emphasizing its dual mechanism of action [6][9] - The company is committed to creating long-term value for shareholders while advancing its clinical programs [35] Other Important Information - The company reported total cash of $274 million at year-end 2025, with a pro forma cash position of approximately $340 million after recent capital raises [32][33] - The Phase 3 trial will enroll approximately 1,800 patients globally, with a focus on both biopsy-confirmed and non-invasive test-assessed MASH patients [21][22] Q&A Session Summary Question: Can the FDA's new single pivotal framework save costs for the Phase 3 trial? - Management indicated that the current approach remains unchanged and the path for approval is through a single trial for accelerated approval [36][38] Question: What are the statistical plans for the Phase 3 trial? - The study is powered for two primary endpoints, with a sample size of around 990 patients, ensuring sufficient power for approval [39][41] Question: What is the FDA's stance on using non-invasive tests as registrational endpoints? - The FDA deemed it premature to consider non-invasive tests for approval, focusing instead on biopsy-driven endpoints [47][48] Question: What are the key elements locked in for the Phase 3 protocol? - The protocol is nearing finalization, with critical elements like sample size and primary endpoints aligned, while finalizing biopsy details [86][87] Question: How will the company proceed with the AUD and ALD trials? - The company plans to assess AUD data and make decisions without waiting for ALD results, focusing on immediate next steps [93]

Financial Data and Key Metrics Changes - Net sales for the fourth quarter were approximately $5.4 billion, an increase of 5.5% over last year [17] - Total comparable club sales, including gasoline, rose 1.6%, with merchandise comparable sales increasing by 2.6% [17][18] - Adjusted EPS for the fourth quarter was $0.96, an increase of 3.2% year-over-year, while full fiscal year Adjusted EPS reached $4.40 [20][22] Business Line Data and Key Metrics Changes - Merchandise comparable sales in perishables, grocery, and sundries grew by 2.3%, driven by solid unit growth [6][18] - General merchandise and services division comp increased by 4.3%, driven by strength in consumer electronics and apparel [18] - Membership fee income rose 10.9% to approximately $129.8 million, supported by healthy acquisition and retention trends [18] Market Data and Key Metrics Changes - The company grew its membership base by over 500,000 members, reaching over 8 million members, a new high [9][10] - Digital sales penetration reached 16%, with digitally enabled sales growing by 31% [10][11] - The company opened 14 new clubs, the most in a single year, expanding into new markets [4][14] Company Strategy and Development Direction - The company aims to continue expanding its footprint with a commitment to open 25 to 30 new clubs over 2025 and 2026 [15][22] - Investments are being made in digital capabilities, supply chain, and real estate to support long-term growth [21][23] - The focus remains on delivering value to members, with a pricing strategy that maintains a competitive edge [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a dynamic environment marked by cautious consumer behavior and macroeconomic volatility [3][16] - The company anticipates comparable sales growth, excluding gas, to be in the range of 2%-3% for fiscal 2026 [22] - Management highlighted the importance of strong membership as the engine for traffic, share gains, and long-term profitable growth [10][27] Other Important Information - The company achieved a 90% tenured renewal rate for the fourth consecutive year, indicating strong member loyalty [9] - The company plans to further invest in its supply chain network and is excited about the upcoming automated distribution center in Ohio [23] Q&A Session Questions and Answers Question: Merchandise margins down 50 basis points - The decline was primarily due to a mix shift towards lower-margin general merchandise, particularly consumer electronics, and investments in value during the quarter [30][33] Question: Growth potential in new markets - The company is optimistic about its growth potential, with successful openings in new states and strong early engagement in the Dallas-Fort Worth area [35][39] Question: Underlying membership trends and MFI increase - Membership fee income growth included contributions from a fee increase, with continued focus on optimizing member acquisition and retention [58][60] Question: Digital growth and fulfillment capabilities - The company is confident in its ability to support digital growth, with ongoing investments in technology and fulfillment capabilities [65][67] Question: Inventory management and discretionary items - The company plans to manage inventory conservatively, particularly in discretionary categories, while ensuring sufficient stock levels [99]

Financial Data and Key Metrics Changes - Consolidated net revenue increased by 2.2% year-over-year on a constant currency basis for Q4, or 4.4% excluding the impact of warrants, driven by solid e-commerce volume growth in North America and increased automation sales [15][10] - For the full year, net revenue increased by 4.7% on a constant currency basis or 6.1% excluding the $5 million headwind associated with warrants [16] - Adjusted EBITDA declined by 10.3% for Q4 on a constant currency basis, or down 1.2% excluding the impact of warrants, bringing the full year's results to down 8.5% on a constant currency basis or down 2.4% excluding the non-cash impact of warrants [21][13] Business Line Data and Key Metrics Changes - Automation achieved nearly 40% growth on a constant currency basis in Q4 and 34.4% growth for the full year, with revenue exceeding $40 million [6][10] - North America saw a 5.5% volume growth in Q4 and 14% for the full year, driven by over 20% growth in void fill and 91.7% growth in automation excluding warrants [10][18] - In Europe and Asia Pacific, combined revenue decreased by 1.4% on a constant currency basis for Q4, primarily due to higher rebate activity and a challenging competitive environment [17] Market Data and Key Metrics Changes - North America experienced a robust e-commerce-led holiday season, particularly in December, contributing to a volume growth of 5.5% in Q4 and 14.3% for the year [5] - Europe showed signs of improvement after a challenging year, with economic fundamentals stabilizing despite ongoing geopolitical uncertainties [12][27] - The input cost environment remained stable, with energy market volatility being a key concern moving forward [12][28] Company Strategy and Development Direction - The company aims to leverage its partnerships with major e-commerce players to drive substantial growth, expecting over $1 billion in cumulative revenue from these relationships over the next 8-10 years [7][23] - Automation is positioned as a hedge against labor shortages and rising costs, with expectations of significant growth in this segment [24][29] - The company is focusing on enhancing its technology stack and operational efficiencies to improve margins and cash generation [20][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the structural forces shaping the packaging and fulfillment landscape, indicating a stable operating environment in North America and an improving outlook in Europe [26][27] - The geopolitical situation, particularly the conflict in the Middle East, poses uncertainties that could impact demand and pricing [28][56] - The company anticipates net revenue growth of 5%-12.7% and Adjusted EBITDA growth of 5.4%-19.9% for 2026, with a focus on driving top-line growth and improving margins [29][30] Other Important Information - The company completed 2025 with a strong liquidity position, holding a cash balance of $63 million and no drawings on its revolving credit facility [22] - CapEx for the year was $30.3 million, reflecting a disciplined approach to capital expenditures [22] Q&A Session Summary Question: What is the PPS volume outlook for 2026 by region? - Management expects meaningful growth in the U.S., potentially high single-digit to double-digit growth, while Europe remains uncertain due to geopolitical factors [35][36] Question: What percentage of PPS growth is driven by customer initiatives with Walmart and Amazon? - Both accounts are expected to drive double-digit growth, with automation equipment playing a significant role in the growth of consumables [40] Question: What is the backlog visibility for the targeted 30%-50% growth in automation for 2026? - The company enters 2026 with its best backlog ever, driven by strong activity in the U.S. and Europe, and confidence in surpassing the lower end of the growth target [42][43] Question: How does the company plan to unlock shareholder value? - Management believes that doubling the top line and driving significant EBITDA growth through strategic relationships and automation will unlock shareholder value [62][64]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's portfolio contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025 [17] - The operating expenses for Q4 2025 were $48.2 million, up from $17.1 million in the prior year, reflecting the expanded cost structure post-Melinta acquisition [17] Market Data and Key Metrics Changes - The company is focusing on maintaining patient utilization rates for DefenCath in outpatient hemodialysis, especially as reimbursement transitions to a bundled add-on mechanism starting July 1, 2026 [6][7] - The guidance for DefenCath in 2026 is set at $150 million-$170 million, with 2027 guidance at $100 million-$125 million [6][8] Company Strategy and Development Direction - The acquisition of Melinta Therapeutics is seen as a significant growth opportunity, adding durable products like MINOCIN and VABOMERE to the portfolio [11] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath, REZZAYO, MINOCIN, and BAXDELA [9] - 2026 is expected to be a transitional year, with a focus on new catalysts and value drivers, particularly the phase 3 ReSPECT data for REZZAYO [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the post-TDAPA environment and maintain growth through strategic pricing and customer negotiations [6][23] - The company is optimistic about the potential for increased Medicare provider reimbursement in 2027, which could lead to a higher net selling price [7] Other Important Information - The company has expanded its workforce significantly, growing from approximately 100 to just under 200 employees, to support growth and operational needs [17] - The company has initiated a share repurchase program, indicating confidence in its financial position and future growth prospects [21] Q&A Session Summary Question: Update on dialysis customer conversations and pricing for DefenCath - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2026 and beyond [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted that the data will guide commercial utility and marketing strategies, with a focus on pathogen data and secondary endpoints [24][25] Question: Developments on TDAPA extension bills and partnerships - Management noted ongoing efforts with legislators and other companies, but timing remains uncertain due to external factors [29][30] Question: Inpatient opportunity with DefenCath and Melinta product growth - Management discussed the current customer mix and potential growth from mid-sized operators, emphasizing the importance of onboarding new customers [33][41]

NACCO Industries (NYSE:NC) Q4 2025 Earnings call March 05, 2026 08:30 AM ET Speaker4Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the NACCO Industries 2025 fourth quarter and full year earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. To ask a question, simply press star one on your telephone keypad. To withdr ...

Financial Data and Key Metrics Changes - In fiscal 2025, net sales grew 6% to $6.553 billion, with adjusted operating income rising 16% to $403 million and adjusted EPS increasing 22% to $3 despite $85 million in net tariff pressure [29][30] - Fourth quarter net sales were $2.27 billion, an increase of 8% year-over-year, with comp sales also up 8% for the second consecutive quarter [29][30] - Adjusted operating income for the fourth quarter was $316 million, exceeding guidance and up from $299 million in the previous year [35][41] Business Line Data and Key Metrics Changes - The Victoria's Secret brand delivered low double-digit growth in the fourth quarter, with the bra business growing mid-single digits and panties significantly accelerating [13][15] - PINK grew high single digits in the fourth quarter, driven by increased apparel penetration and renewed momentum in bras [17][18] - The beauty segment grew low single digits, with fine fragrance continuing to lead the business [21][32] Market Data and Key Metrics Changes - International net sales increased 43% year-over-year, primarily driven by strong performance in China [11][32] - Adjusting for the shift in reporting European digital sales, international sales grew 27% [32] - The total intimates business across Victoria's Secret and PINK grew at a high single-digit rate, with low single-digit market share gains [31][24] Company Strategy and Development Direction - The company is executing its "Path to Potential" strategy, focusing on four pillars: supercharging bra authority, recommitting to PINK, fueling growth in beauty, and evolving brand projection [6][12] - The strategy aims to restore leadership in bras, reignite PINK, and grow the beauty business, with a clear roadmap and disciplined execution [6][12] - The company plans to expand in existing and new markets, maximizing digital and social commerce opportunities [12][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum entering fiscal 2026, with expectations for continued top-line growth despite macroeconomic uncertainties [26][49] - The company anticipates net sales for fiscal 2026 to be in the range of $6.85 billion to $6.95 billion, representing growth of approximately 5%-6% [41][42] - Management highlighted the importance of customer acquisition and retention, noting growth across all income cohorts and a positive outlook for younger customers [53][54] Other Important Information - The company initiated a strategic review of its DailyLook and Adore Me businesses, with plans to optimize their roles within the portfolio [38][39] - The company recorded a non-cash pre-tax impairment charge of $120 million related to Adore Me's long-lived assets [39] - The company expects to maintain a disciplined cadence of brand-building moments and product innovation throughout 2026 [25][49] Q&A Session Summary Question: Customer acquisition trends and marketing improvements - Management noted growth in new customer acquisition, particularly among younger demographics, and emphasized ongoing marketing improvements [53][54] Question: Momentum in the first quarter and demand drivers - Management highlighted strong traffic and sales momentum from the holiday season and Valentine's Day, setting a positive outlook for Q1 [56][60] Question: Market share trends and brand potential - Management expressed optimism about market share gains across key categories, particularly in bras and intimates, and indicated significant growth potential for all brands [64][70] Question: Tariff impact throughout the year - Management explained that the first quarter would see the most significant tariff impact, with expectations of mitigation efforts improving in the second half of the year [76][77]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the impact of the Advanced Rehabilitation divestiture [20][21] - Adjusted EBITDA for the quarter was $37 million, an increase of $8 million or 30% year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points compared to the previous year [21][22] - Cash flow from operations totaled approximately $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full year objective of nearly doubling cash flow from operations, achieving a 92% increase for the year [26][28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [23] - Surgical solutions revenue increased by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [23] - Restorative therapies revenue declined by 26% due to the divestiture of the Advanced Rehabilitation business, but organic growth was 10% excluding this impact [24] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged compared to the prior year, with organic growth climbing 10% [24] - The international segment achieved 11% organic growth for the year, supported by a new team and improved commercial execution [24] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [5][10] - In 2026, the company plans to invest approximately $13 million in growth drivers such as PNS, PRP, Ultrasonics, and international business [11][12] - The focus will be on driving above-market growth across core businesses, particularly the HA franchise, while also investing in marketing and R&D to support growth [11][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and strong foundation, indicating a focus on becoming a $1 billion leading med tech company [5][18] - The company anticipates earnings growth to outpace revenue growth, maintaining an EBITDA margin of approximately 20% for 2026 [17][18] - Management highlighted the importance of leveraging profitable growth to fund future growth drivers, emphasizing a long-term approach to business [40] Other Important Information - The company refinanced its term loan, enhancing liquidity and driving interest expense savings [10] - The company expects net sales for 2026 to range from $600 million to $610 million, with adjusted earnings per share projected at $0.73 to $0.77 [27][28] Q&A Session Summary Question: Growth contribution year-over-year from price in pain treatments - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][35] Question: Assumptions by segment for 2026 growth - Management expects low to mid-single digit growth in restorative therapies and mid to high single digit growth in the pain portfolio, with double-digit growth anticipated in surgical solutions [36][38] Question: Impact of favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [45] Question: Learnings from the PNS pilot phase - Positive feedback was received regarding the technology's power, size, and ease of use, with plans to scale the business aggressively based on these insights [48][50]

Financial Data and Key Metrics Changes - For the full year of 2025, revenue was approximately $237,000, an increase from $96,000 in 2024 [6] - Net loss was approximately $20.3 million or a loss of $0.16 per share, an improvement from $22.5 million or a loss of $0.19 per share in 2024 [7] - R&D investment was approximately $11.5 million compared to $16.8 million in the prior year [7] - G&A expense was approximately $9.5 million compared to $6.4 million in the prior year [7] - Year-end cash position was approximately $69 million, roughly double the $34.9 million at the end of the third quarter [7] Business Line Data and Key Metrics Changes - Customer programs deepened in 2025, with three programs advanced to stage 3, prototype to final product [6] - Approximately 15 additional engagements are progressing through stage 1 and stage 2 [6] - The focus is on building durable, repeatable revenue streams supported by qualification and design wins [10] Market Data and Key Metrics Changes - The market for Ethernet optical transceivers of 100G and above and CPO reached approximately $16.5 billion in revenue in 2025, projected to reach approximately $26 billion in 2026, corresponding to a 60% growth rate [15] - AI clusters are expected to consume roughly 80% of Ethernet transceivers and CPO through 2031 [15] - 1.6 terabit per second transceivers revenue are expected to reach $1 billion in 2026 [15] Company Strategy and Development Direction - The strategy is to enhance silicon photonics rather than compete against it, allowing for higher bandwidth with lower power per bit [12] - The focus for 2026 includes advancing stage 3 programs towards qualification milestones, converting technical engagements into structured commercial agreements, and broadening the electro-optic polymer-ready silicon foundry ecosystem [17] - The company is preparing for scalable integration and not boutique deployment, with a disciplined approach to operational readiness [14] Management's Comments on Operating Environment and Future Outlook - The company remains confident in the AI opportunity and is committed to building long-term shareholder value [18] - The operational discipline is emphasized as critical for creating durable companies, with a focus on effective internal controls and IP protection [17] - The timeline for volume production and licensing revenues is not anticipated until 2027 at the earliest, reflecting the rigorous qualification cycles in the industry [10] Other Important Information - The company completed a public offering in December 2025, raising approximately $32.8 million in net proceeds [7] - The company is managing capital deliberately, with every dollar allocated towards commercialization readiness [8] - Device characterization and performance validation are expected in mid-2026 [13] Q&A Session Summary Question: What specific milestones remain to complete the technology transfer? - The company intends to proceed with back-end of line process and capacity expansion in Denver to support prototyping and final product qualification [20] Question: Can you provide guidance on production volume requirements for 2026? - The company is planning for success with aggressive assumptions related to production capacity and technician requirements [21] Question: Can shareholders expect to see an EOP modulator-based pluggable transceiver prototype completed this year? - The company will continue to update on progress towards stage four throughout 2026, but does not control the full transceiver program [22] Question: How will shareholders be updated regarding product progression with tier one partners? - The company will provide visibility through quarterly financial and business update calls [23] Question: What specific performance metrics will be validated for the mid-2026 device characterization? - The tapeout is a significant milestone to validate key design and performance parameters for modulators [24]